Cilostazol vs pentoxifylline for the treatment of patients with intermittent claudication Review article
Article Sidebar
Published:
Sep 30, 2017
Keywords:
cilostazol, pentoxifylline, atherosclerosis obliterans, chronic lower limb ischemia, intermittent claudication
Main Article Content
Abstract
Atherosclerosis obliterans of the lower limb arteries in the initial stage is characterized by intermittent claudication depending on the severity of its changes. The progression of peripheral artery disease may lead to artery stenosis, then their occlusion. Risk factors for the development of atherosclerosis obliterans are: older age, male gender, smoking, diabetes, dyslipidemia and hypertension.
Article Details
How to Cite
Wojtak, A., & Zubilewicz, T. (2017). Cilostazol vs pentoxifylline for the treatment of patients with intermittent claudication. Medycyna Faktow (J EBM), 10(3(36), 270-274. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2138
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Bennett P.C., Silverman S., Gill P.S., Lip G.Y.: Ethnicity and peripheral artery disease. QJM 2009; 102: 3-16.
2. Ouriel K.: Peripheral arterial disease. Lancet 2001; 348: 1257-1264.
3. Kim E.S., Wattanakit K., Gornik H.L.: Using the anklebrachial index to diagnose peripheral artery disease and assess cardiovascular risk. Cleve. Clin. J. Med. 2012; 79 (9): 651–661.
4. Bramer S.L., Tata P.N.V., Mallikaarjun S.: Disposition of 14 C-cilostazol after single dose administration to healthy human subjects. Phar. Res. 1997; 14(suppl): S612.
5. Takahashi S., Oida K., Fujiwara R. et al.: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J. Cardiovasc. Pharmacol. 1992; 20: 900-906.
6. Reilly M.P., Mohler E.R. 3rd: Cilostazol: treatment of intermittent claudication. Ann. Pharmacother. 2001; 35: 48-56.
7. Elam M.B., Heckman J., Crouse J.R. et al.: Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler. Thromb. Vasc. Biol. 1998; 18: 1942-1947.
8. Yoshitomi Y., Kojima S., Sugi T. et al.: Antiplatelet treatment with cilostazol after stent implantation. Heart 1999; 80: 393-396.
9. Norgren L., Hiatt W.R., Dormandy J.A. et al.: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur. J. Vasc. End. Surg. 2007; 33(suppl. 1).
10. Dawson D.L., Cutler B.S., Meissner M.H., Strandness D.E. Jr: Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-686.
11. Dawson D.L., Cutler B.S., Hiatt W.R. et al.: A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am. J. Med. 2000; 109: 523-530.
12. Thompson P.D., Zimet R., Forbes W.P., Zhang P.: Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Cardiol. 2002; 90: 1314-1319.
13. Lindgarde F., Jelnes R., Bjorkman H. et al.: Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989; 80: 1549-1556.
2. Ouriel K.: Peripheral arterial disease. Lancet 2001; 348: 1257-1264.
3. Kim E.S., Wattanakit K., Gornik H.L.: Using the anklebrachial index to diagnose peripheral artery disease and assess cardiovascular risk. Cleve. Clin. J. Med. 2012; 79 (9): 651–661.
4. Bramer S.L., Tata P.N.V., Mallikaarjun S.: Disposition of 14 C-cilostazol after single dose administration to healthy human subjects. Phar. Res. 1997; 14(suppl): S612.
5. Takahashi S., Oida K., Fujiwara R. et al.: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J. Cardiovasc. Pharmacol. 1992; 20: 900-906.
6. Reilly M.P., Mohler E.R. 3rd: Cilostazol: treatment of intermittent claudication. Ann. Pharmacother. 2001; 35: 48-56.
7. Elam M.B., Heckman J., Crouse J.R. et al.: Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler. Thromb. Vasc. Biol. 1998; 18: 1942-1947.
8. Yoshitomi Y., Kojima S., Sugi T. et al.: Antiplatelet treatment with cilostazol after stent implantation. Heart 1999; 80: 393-396.
9. Norgren L., Hiatt W.R., Dormandy J.A. et al.: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur. J. Vasc. End. Surg. 2007; 33(suppl. 1).
10. Dawson D.L., Cutler B.S., Meissner M.H., Strandness D.E. Jr: Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-686.
11. Dawson D.L., Cutler B.S., Hiatt W.R. et al.: A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am. J. Med. 2000; 109: 523-530.
12. Thompson P.D., Zimet R., Forbes W.P., Zhang P.: Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Cardiol. 2002; 90: 1314-1319.
13. Lindgarde F., Jelnes R., Bjorkman H. et al.: Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989; 80: 1549-1556.